Thermo Fisher done with big deals ... for now

Acquisition-hungry Thermo Fisher Scientific ($TMO) is taking it down a notch in 2012. CEO Marc Casper tells Bloomberg that after making 5 acquisitions last year, it will use its cash to pay down its $7 billion in debt. Last year, Thermo Fisher made news with its $3.5 billion acquisition of Phadia and $2.1 billion purchase of Dionex. But it may be a little weary after those big buys. Although Casper's company will keep its eye open for deals, he doesn't see larger transactions happening "any time soon." Report

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.